Author's summary Although the global digital therapeutics (DTx) market is rapidly growing and whether the health insurance system will cover DTx is a very important issue, there are currently no standards in Korea after the approval stage of the Ministry of Food and Drug Safety. Regarding this issue, this study examined the concepts and characteristics of DTx and compared major countries (the U.S., the U.K., Germany, Japan, and Australia) reimbursement policies for DTx, thus clarifying the political implications for introducing DTx in Korea.

No abstract